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Bioinformatics Integration Support Contract (BISC)
• NIH/NIAID/DAIT would like to:
– maximize the return on the public investment in basic, translational and clinical
research
– allow investigators to more effectively extract meaningful information from the
vast amounts of data generated from advanced research technologies
• Bioinformatics Integration Support Contract (BISC) to support all DAIT-
funded programs - basic, translational and clinical research
• Immunology Database and Analysis Portal (ImmPort) - www.ImmPort.org
– Archive and manage basic and clinical research data
– Analyze experiment data
– Integrate with extensive biological knowledge
– Analyze integrated data
– Build upon data generated by previous studies
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3ImmPort Overview - System Components
• Semi-public web-based database and analysis
portal
– Multi-level access control
– Data sharing
• Data
– Reference data
• Types - Gene structure, protein function,
polymorphisms, metabolic, regulatory, signaling and
other networks, protein-protein, gene-gene, host-
pathogen interactions
• Sources - NCBI, Uniprot, Swissprot, BIND, Reactome
– Experiment data
• Methodologies – microarrays, SNP genotyping, flow
cytometry, ELISA, ELISPOT, qPCR, imaging, etc.
• Metadata (defining how the experiment was
performed) - common features of all experiments
• Primary results - from all experiment measurement
techniques
• Processed results
– Interpreted results
– Analytical metadata
– Clinical research data
• Study design – from clinical protocol
• Participant characteristics/phenotype – from
assessments captured in CRF’s and laboratory testing
• Query tools
– To support retrieval of reference and experiment
data based on specified criteria
– Pre-defined QBE
– Customized semantic queries
• Ontology
– Thesaurus function
– Organize terms and define relationships
• Analysis tools
– Genetic analysis
• LD analysis
• TagSNP selection
• Haplotype reconstruction
• Genotype-phenotype association
– Gene expression analysis
• Filtering/normalization
• Clustering
• Classification
– Cell population analysis
• Standard FACS statistics
• Novel population identification based on high
dimensional data clustering
– Measurement of immune response (e.g.,
ELISA, ELISPOT)
• Statistical analysis of distributions
– Biological network analysis
• Quantification of topological parameters
• Module identification
• Visualization tools
– Genome display, including genes, introns, exons,
SNPs, tagSNPs, etc.
– Genetic analysis results
– Gene expression results
– Networks, pathways, and molecular interactions
– Graphing and charting of statistical results
4Initial work
• Population Genetics Analysis Program: Immunity to
Vaccines/Infections (PopGen)
• Immune Function and Biodefense in Children, Elderly, and
Immunocompromised Populations (Special Pops)
• HLA Region Genetics in Immune-mediated Diseases
• Immune Tolerance Network (ITN)
• Atopic Dermatitis and Vaccinia Network (ADVN)
• NIAID non-human primate colony
5Varicella:
Immune Response to Varicella Vaccination in Subjects
with Atopic Dermatitis Compared to Nonatopic
Controls
Objectives:
To determine if children with AD have Varicella-
specific cell mediated immune (CMI) responses
to varicella vaccination that differ from those of
nonatopic controls (Th2)
Endpoint:
1. ELISPOT: number of Varicella-specific T-cell
2. ELISA: levels of Varicella-specific antibodies
3. Flow cytometry: perforin generation using 2-color
flow cytometry staining for both CD8 and
perforin.
(Perforin levels, which may contribute to defects
in CD8+ cytotoxic T lymphocyte function).
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7Driving Projects - ADVN
Why OBX?
• Challenges
– Extensive phenotypic characteristics of interest
– Complex study designs of treatments, assessments, samplings, etc.
– Few standards for how they are described or captured
– Each supported project captures their data in a different format
– Integration with mechanistic studies of specimens
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• Evaluation of existing clinical data standards
– BRIDG – designed for supporting the conduct of clinical trials, not a study
repository optimized for analysis
– CDISC STDM – specification for SAS transport files to the FDA
– CDISC CDASH – models clinical encounters, but not sequence of events;
requires use of EPOCHs (contiguous blocks of time)
– None designed to manage mechanistic studies
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• Ontology-Based eXtensible Data Model (OBX)
– Logical ontology structure (BFO/OBI)  => extensible data model
– Data element value sets derived from ontology hierarchy
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Entities of Interest
• Objects
– Human subjects
– Specimens
– Materials
– Plans
• Qualities – clinical phenotype
– Malar rash
– WBC count
– Weight
– Blood glucose levels
– Atopic dermatitis
• Roles
– Principal investigator, study
coordinator, study participant
– Reagent, therapeutic
• Processes
– Recruitment, enrollment, approval
– Assays, physical exams
– Blood draw, PBMC isolation
– Treatment, surgery (interventions)
• Context
– Time
– Environment
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OBX Framework
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OBX Study Design
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OBX Biomaterial Transformation
Assay Database Schema
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Blood Test:
Lab test mapping into OBX
ADVN Fields ADVN Fields Description ImmPort Table ImmPort Attribute
ID Subject ID Lab Test          Subject ID
SITE Study Site will not capture
VISITDT VISIT Date Lab Test          Visit Date
HGB Hemoglobin (g/dl): Lab Test
         Type = Blood Test
Subtype = Hemoglobin Measurement
Test Result Value = HGB
Test Result Unit = grams per deciliter
Clinical Significance = CSHGBCSHGB Hemoglobin Clinical Significant Lab Test
HCT Hematocrit (%): Lab Test
         Type = Blood Test
Subtype = Hematocrit Measurement
Test Result Value = HCT
Test Result Unit = percentage
Clinical Significance = CSHCTCSHCT Hematocrit Clinical Significant Lab Test
WBC Total WBC (x1000/µl): Lab Test
         Type = Blood Test
Subtype = Total White Blood Cell
Measurement
Test Result Value = HGB
Test Result Unit = 1000/µl
Clinical Significance = CSHGBCSWBC Total WBC Clinical Significant Lab Test
NEUT Neutrophils (x1000/microliter): Lab Test
         Type = Blood Test
Subtype = Neutrophils Measurement
Test Result Value = NEUT
Test Result Unit = 1000/µl
Clinical Significance = CSNEUTCSNEUT Neutrophils Clinical Significant Lab Test
LYMP Lymphocytes (x1000/µl): Lab Test
         Type = Blood Test
Subtype = Lymphocytes Measurement
Test Result Value = LYMP
Test Result Unit = 1000/µl
Clinical Significance = CSLYMPCSLYMP Lymphocytes Clinical Significant Lab Test
EOSIN Eosinophils (x1000/µl): Lab Test
         Type = Blood Test
Subtype = Eosinophils Measurement
Test Result Value = EOSIN
Test Result Unit = 1000/µl
Clinical Significance = CSEOSCSEOS Eosinophils Clinical Significant Lab Test
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Load File Examples
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Summary
• OBX is an ontology-informed clinical research data model
• Ontological framework incorporated provides for
extensibility and straightforward incorporation of ontology
terms as value sets
• Ontological framework also facilitated distributed data
model development and guides ongoing mapping strategies
• Successfully loaded two large, distinct clinical studies
• Building the user interfaces for data extraction and analysis
• Refinement through use – mapping, loading, extracting,
analysis
• Term submission to OBO Foundry ontologies, especially
OBI
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